First Ovarian Tissue Cryopreservation and Autotransplantation in Patients with Malignancies in Hungary – Report of the First Three Cases – Pages 68-72

Attila Vereczkey1,*, Karolina Varga1, László Landherr2, Ibolya Czegle3, Zsolt Benedek1 and Éva Margittai1

1Versys Clinics – Human Reproduction Institute, Budapest, Hungary,
2Department of Oncoradiology, Uzsoki Hospital, Budapest, Hungary and 33rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

DOI: https://doi.org/10.31907/2309-4400.2020.08.12

Abstract:

Autotransplantation of cryopreserved ovarian tissue is one of the most advanced methods for
fertility preservation of patients suffering from malignant diseases. Even though the method itself is still experimental, nearly a hundred live births have been documented worldwide, and its efficacy is
comparable with the efficacy of any other assisted reproductive technology. Our prospective, nonrandomized study was the first in Hungary that aimed to examine the safety and efficacy of fertility preservation based on ovarian tissue cryopreservation and autotransplantation. Patients were included only with stage I-III malignancy confirmed by histological diagnosis with a high risk for post-treatment infertility. 13 patients met the inclusion criteria and were enrolled in the study. After successful treatment and recovery, cryopreserved ovarian tissue was thawed and autotransplanted in three cases. The ultrathin slices of ovarian cortex were transplanted on the remaining ovaries with laparoscopic or minilaparotomic intervention. Patients were discharged home after an uneventful postoperative period and are followed up currently. In summary, cryopreservation and autotransplantation of ovarian tissue is a safe technology for fertility preservation, which should be considered to offer and perform prior to gonadotoxic treatment, after individual evaluation of patients.

Keywords: Fertility Preservation, Cryopreservation, Ovarian Tissue Autotransplantation and Malignancies.